FSCN1 is an effective marker of poor prognosis and a potential therapeutic target in human tongue squamous cell carcinoma

Chen, Yue; Tian, Tian; Li, Zhiyong; Wang, Chunyang; Deng, Rong; Deng, Weiye; Yang, Ankui; Chen, Yanfeng; Li, Hao

doi:10.1038/s41419-019-1574-5

Cited by 29 publications

(22 citation statements)

References 34 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Out of 131 samples of OSCC studied by Alam et al, only 74.80% of the cases showed fascin staining while it was not detected in 25.19% of the cases. 26 In a study by Chen et al in 106 cases of tongue 26,27 In our study, fascin expression seems to be increasing from well to moderate to poor OSCC (Table 3 and Fig. 5).…”

Section: Discussionsupporting

confidence: 61%

See 1 more Smart Citation

Immunohistochemical Expression of Fascin in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma

Natesan¹,

Ramakrishnan²,

Krishnapillai³

et al. 2019

World Journal of Dentistry

View full text Add to dashboard Cite

Aims: The present study aimed to evaluate and compare the expression of fascin in normal oral mucosa (NOM) and oral epithelial dysplasia (OED) and to estimate the expression in different grades of oral squamous cell carcinoma (OSCC). Materials and methods:The study involves a total of 55 cases including 30 cases of OSCC, 15 cases of OED, and 10 NOM tissues. All the sections were subjected to fascin immunostaining. Epithelial dysplasia were scored by layer-wise immunohistochemical staining, while for carcinoma staining intensity and number of cells stained were assessed. The scores were analyzed using one-way ANOVA test and Tukey's post hoc test. Results: Our results showed that fascin expression in NOM was very low or restricted to the basal layers of the epithelium. In case of OED and OSCC, fascin immunostaining was highly elevated. Also, it was seen increasing with increasing grades of dysplasia (p = 0.002) and decrease in differentiation of OSCC. Conclusion:A steady up-regulation of fascin expression is noted in OED and squamous cell carcinoma. These findings suggest that fascin plays an important role from early stages of carcinogenesis to invasive carcinoma. Clinical significance: Fascin can be used as a reliable biomarker for diagnostic and prognostic implications of OED and OSCC, respectively.

show abstract

Section: Discussionsupporting

confidence: 61%

“…Comparison of fascin expression patterns in NOM and OED (Tukey's post hoc test) 2% of cases exhibited high fascin expression, while 34.9% of cases showed relatively low fascin 27. This disparity of fascin immunoreactivity between studies could be attributed to the difference in sample size, the methods of evaluation of staining, or technical errors.…”

mentioning

confidence: 99%

Immunohistochemical Expression of Fascin in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma

Natesan¹,

Ramakrishnan²,

Krishnapillai³

et al. 2019

World Journal of Dentistry

View full text Add to dashboard Cite

show abstract

“…[30][31][32] FSCN1 has been reported to support the invasion and metastasis of various cancer cells. [33][34][35] In this study, HBEGF and FSCN1 were also shown to be potential targets for SOX2 in breast cancer. Ectopic expression of SOX2 upregulated HBEGF and FSCN1 expression, and SOX2 knockdown reduced the expression of HBEGF and FSCN1.…”

Section: Discussionmentioning

confidence: 63%

SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF

Xiao

Zheng

Xie

et al. 2020

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

The prognosis of breast cancer brain metastasis (BCBM) is extremely poor due to its resistance to conventional therapy. Elucidation of the molecular mechanisms of BCBM could contribute to the development of new therapeutic targets. In this study, we isolated RNA samples from primary breast cancer or BCBM, and then performed mRNA profiling. We determined that SOX2 is associated with the occurrence of BCBM and could be a predictor of BCBM. High levels of SOX2 were significantly associated with decreasing BCBMfree survival in patients. Overexpression of SOX2 in breast cancer cells enhanced cancer cell adhesion to brain microvascular endothelial cells, transendothelial migration, and in vitro blood-brain barrier (BBB) migration, whereas silencing SOX2 inhibited these events. SOX2 can increase cancer cell migration and BBB permeability by upregulating FSCN1 and HBEGF, thereby promoting BBB migration of breast cancer cells. Moreover, high levels of FSCN1 and HBEGF were significantly associated with reducing BCBM-free survival in breast cancer patients. Further study indicated that SOX2 mediates the expression of HBEGF and FSCN1 by activating AKT and b-catenin signaling pathways. Additionally, in vivo experiments showed that SOX2 promotes the development of BCBM. This study demonstrated that SOX2 promotes BCBM by upregulating the expression of FSCN1 and HBEGF.

show abstract

“…FSCN1 is a member of the fascin family of actin-binding proteins, and regulates cellular migration, motility, adhesion, and inter-cellular interactions [ 37 ]. The oncogenic role of FSCN1 has been described in multiple cancers including ESCC [ 24 , 38 – 40 ]. FSCN1 is targeted by multiple lncRNA-miRNA pairs in ESCC such as PVT1-miR-145, TTN-AS1-miR-133, and ROR-miR-145 [ 41 – 43 ].…”

Section: Discussionmentioning

confidence: 99%

LncRNA LOC146880 promotes esophageal squamous cell carcinoma progression via miR-328-5p/FSCN1/MAPK axis

Tang

Liu

et al. 2021

Aging

View full text Add to dashboard Cite

We investigated the role of long non-coding RNA (lncRNA) LOC146880 in esophageal squamous cell carcinoma (ESCC). LOC146880 was significantly upregulated in ESCC tissues ( n = 21) and cell lines compared to the corresponding controls. Higher LOC146880 expression correlated with poorer overall survival (OS) of ESCC patients. Moreover, CREB-binding protein (CBP) and H3K27 acetylation levels were significantly higher in the LOC146880 promoter in ESCC cell lines than in the controls. LOC146880 silencing inhibited in vitro proliferation, invasion, migration, and epithelial-mesenchymal transition of ESCC cells. LOC146880 silencing also induced G1-phase cell cycle arrest and apoptosis in ESCC cells. Bioinformatics analysis, dual luciferase reporter assays, and RNA immunoprecipitation assays showed that LOC146880 regulates FSCN1 expression in ESCC cells by sponging miR-328-5p. Moreover, FSCN1 expression correlated with activation of the MAPK signaling pathway in ESCC cells and tissues. In vivo xenograft tumor volume and liver metastasis were significantly reduced in nude mice injected with LOC146880-silenced ESCC cells as compared to those injected with control shRNA-transfected ESCC cells. These findings show that the LOC146880/miR-328-5p/FSCN1/MAPK axis regulates ESCC progression in vitro and in vivo . LOC146880 is thus a promising prognostic biomarker and potential therapeutic target in ESCC.

show abstract

FSCN1 is an effective marker of poor prognosis and a potential therapeutic target in human tongue squamous cell carcinoma

Cited by 29 publications

References 34 publications

Immunohistochemical Expression of Fascin in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma

Immunohistochemical Expression of Fascin in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma

SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF

LncRNA LOC146880 promotes esophageal squamous cell carcinoma progression via miR-328-5p/FSCN1/MAPK axis

Contact Info

Product

Resources

About